Rafael Rafols, MD
Family Medicine · Edinburg, TXNPI 1609028612
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Convatec Inc. accounts for 74.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $10,605 and has fallen 58.6% since, to $4,392 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $132.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$27K
- Misonix Inc$3K
- Smith+Nephew$2K
- Bioventus LLC$1K
- Triad Life Sciences Inc.$750
- Progenacare Global, LLC$296
- plus $2K from 18 others
What the payments were for
- Consulting fees$21,47558%
- Travel & lodging$5,04014%
- Food & beverage$10,36028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 32 | $27,388 |
| Misonix Inc | 45 | $2,585 |
| Smith+Nephew | 116 | $1,938 |
| Bioventus LLC | 18 | $1,463 |
| Triad Life Sciences Inc. | 3 | $750 |
| Progenacare Global, LLC | 1 | $296 |
| AbbVie | 4 | $284 |
| Medela LLC | 7 | $264 |
| Medline Industries LP | 3 | $253 |
| Osiris Therapeutics Inc. | 24 | $210 |
| KCI USA, Inc. | 5 | $208 |
| Next Science LLC | 8 | $185 |
| Kerecis Limited | 1 | $163 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Amnio Technology, LLC | 2 | $118 |
| Organogenesis Inc. | 1 | $112 |
| Polarityte, Inc. | 1 | $96 |
| Abbott | 1 | $96 |
| Cardiovascular Systems Inc. | 1 | $94 |
| Integra Lifesciences Corporation | 1 | $78 |
| TEI Biosciences Inc | 1 | $77 |
| Pulmonx Corporation | 1 | $47 |
| Hydrofera LLC | 1 | $23 |
| Reddress USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUACEL AG$20,117
- AQUACEL FOAM$6,392
- InnovaMatrix AC$1,027
- Kerecis Omega3 SurgiClose$490
- TheraSkin$410
- TEFLARO$251
- Other$242
- CONVATEC INC.$237
- MEDLINE INDUSTRIES, INC.$171
- Kerecis Omega3 GraftGuide$163
- Kerecis Omega3 Marigen$163
- AVYCAZ$126
- AQUACEL Ag Advantage$125
- NUZYRA$125
- Grafix PRIME$125
- Grafix CORE$125
- Grafix XC$125
- Grafix PL PRIME$125
- Stravix$125
- DALVANCE$125
How this compares
$36,874 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 163 | $123,305 |
| Gentamicin Sulfate | 40 | $2,025 |
| Doxycycline Hyclate | 118 | $1,179 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 42 | $446 |
| Lidocaine | 16 | $408 |
| Nystatin | 22 | $353 |
| Mupirocin | 22 | $256 |
| Clotrimazole | 12 | $241 |
| Triamcinolone Acetonide | 21 | $197 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $82 |
| Levofloxacin | 32 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,938 | $123,305163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Edinburg
- Jose LedezmaEdinburg$300K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.